Starting stock price: $4.85
Ending stock price: $1.03
Percent Change: -78.76%
Details: Iomai reported in May that it's needle-free flu vaccine demonstrated less of an immune response than an injection, sending its stock down 35%. The company is also developing a patch for traveler's diarrhea that has delivered promising results, and is working on two immunostimulant patches for pandemic flu.
Iomai vax patch guards against traveler's diarrhea. Report
Vaccine-maker Iomai files $83M IPO. Report